# SNV1521 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06220864/  
OnCo record `nct06220864` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06220864 as recruiting, last updated 2026-06-25. Enrolment is 400 planned participants, an estimate. Interventions: SNV1521, DB-1310, Abiraterone, Darolutamide. Primary measures include Safety of SNV1521; Tolerability of SNV1521. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT06220864
- Phase: 1
- Setting: A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
- Sponsor: Synnovation Therapeutics, Inc.

## Sources

- ClinicalTrials.gov NCT06220864: https://clinicaltrials.gov/study/NCT06220864

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [SNV1521](https://onco.cc/drugs/snv1521/)

---
JSON: https://onco.cc/api/v1/entities/nct06220864.json